Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced Or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

Journal article

Peer reviewed

J. M. Hubbard, M. R. Mahoney, W. S. Loui, L. R. Roberts, T. C. Smyrk, Zoran Gatalica, M. Borad, S. Kumar and S. R. Alberts

Targeted Oncology, Vol.12(2), pp.201-209

04/2017

PMID: 27943153

Metrics

5 Record Views

Title: Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced Or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
Creators: J. M. Hubbard (Author)
M. R. Mahoney (Author)
W. S. Loui (Author)
L. R. Roberts (Author)
T. C. Smyrk (Author)
Zoran Gatalica (Author) - Creighton University
M. Borad (Author)
S. Kumar (Author)
S. R. Alberts (Author)
Additional links: http://doi.org/10.1007/s11523-016-0467-0
Publication Details: Targeted Oncology, Vol.12(2), pp.201-209
Number of pages: 201-209
Identifiers: 991005931338502656
Academic Unit: School of Medicine; Pathology
Resource Type: Journal article